Biotech News
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
investors.vaxcyte.com2026-05-06 14:45 EST
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants.